Stage III Primary Peritoneal Cancer

Drug	Drug Name	Drug Description
DB00112	Bevacizumab	A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.

Drug	Drug Name	Target	Type
DB00112	Bevacizumab	Vascular endothelial growth factor A	target
DB00112	Bevacizumab	Complement C1q subcomponent subunit A	target
DB00112	Bevacizumab	Complement C1q subcomponent subunit B	target
DB00112	Bevacizumab	Complement C1q subcomponent subunit C	target
DB00112	Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor III-A	target
DB00112	Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor II-a	target
DB00112	Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor II-b	target
DB00112	Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor II-c	target
DB00112	Bevacizumab	High affinity immunoglobulin gamma Fc receptor I	target

Drug	Drug Name	Phase	Status	Count
DB00958	Carboplatin	2	Terminated	1
DB01229	Paclitaxel	2	Terminated	1
DB00515	Cisplatin	3	Recruiting	1